No trade signal. This is a standard employee compensation grant with no immediate financial or strategic implications. Monitor next quarterly filing for any changes in outstanding share count from ongoing equity programs.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $25.24entry
- T+1 · 5mo ago −0.63%α −1.17% · $25.08
- T+5 · 5mo ago +0.59%α +0.16% · $25.39
- T+20 · 4mo ago +17.99%α +16.10% · $29.78
- T+60 · 2mo ago +33.12%α +28.73% · $33.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab A/S filed a 6-K reporting a routine grant of 15,894 restricted stock units and 15,494 warrants to employees. The grants are standard long-term incentive compensation with 3-year vesting, representing a minimal and immaterial dilution relative to the company's $15.7B market cap.
Key Facts
- Grant of 15,894 restricted stock units and 15,494 warrants to employees on June 11, 2026.
- RSU fair value of DKK 1,616.50 per unit (closing price on grant date); warrant fair value of DKK 534.23 per warrant (Black-Scholes).
- Both instruments vest three years from grant date; warrants expire at the seventh anniversary.
- The awards are cost-free to recipients; exercise price per warrant is DKK 1,616.50.
- Total potential dilution is negligible relative to Genmab's outstanding share count (~$15.7B market cap).
Financial Impact
Immaterial, combined fair value of roughly DKK 33.9M (~$4.8M) based on RSU fair value of ~DKK 25.7M and warrant fair value of ~DKK 8.3M; this is less than 0.03% of market cap.
Risk Factors
- None from this filing; equity compensation programs are routine for a biotech company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000087 |
| Document: gmab_20260611xx6k.htm | 0001434265-26-000087 |
| Document: 0001434265-26-000087-index-headers.html | 0001434265-26-000087 |
| Document: 0001434265-26-000087-index.html | 0001434265-26-000087 |
| Document: 0001434265-26-000087.txt | 0001434265-26-000087 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers